CD19 and diffuse large B-cell lymphoma: Loncastuximab tesirine (ADCT-402) is a humanized anti-CD19 mAb conjugated to a pyrrolobenzodiazepine dimer toxin, currently approved as a single agent in R/R DLBCL.